Rate of TEs in our PNH cohort. (A-B) Bar charts show thrombosis rates per 1000 patient-years in our cohort according to PNH granulocytes and RBC clone sizes. (C) Bar chart on the left indicates rate of thrombosis based on receiving or not receiving anticomplement treatment, and on the right a subanalysis on treated cases according to the type of complement inhibitors received is shown. (D) Cumulative incidence of thrombosis in hemolytic disease is shown. At 2 years, the incidence of thrombosis was 18.3% (12.8%-24.7%) in untreated (death and anticomplement treatment initiation as competing events) vs 3.9% (1.3%-9.1%) upon therapy commencement (landmark time = treatment start, death as competing event). Numbers at risk are indicated below the curve.